ChemoCentryx - Top 20 VC deals of 2008

Chemocentryx, Fiercebiotech's top venture capital deals of 2008Company: ChemoCentryx
Based: Mountain View, CA
Amount: $50M

Investors: HBM BioVentures, Undisclosed Firm, Odlander, Fredrikson, OrbiMed Advisors, Alta Partners, Undisclosed Firm

Scoop: ChemoCentryx dropped an IPO in 2008 but was able to raise $50 million in funding. The company is developing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx's most advanced program is Traficet-EN, which is in Phase III trials for Crohn's disease, Phase II for Celiac disease and Phase I for ulcerative colitis. Additionally, the company is in Phase I trials for several other drug candidates: CCX025 for gastrointestinal diseases, CCX140 for vascular restenosis and multiple sclerosis, and CCX 354 for rheumatoid arthritis.

ChemoCentryx - Top 20 VC deals of 2008
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.